LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON (IMNN), Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that new ...
IMUNON, Inc. announced promising results from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for advanced ovarian cancer, which demonstrated significant improvements in overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results